Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer

Background Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Oncology Pharmacy Practice 2021-03, Vol.27 (2), p.405-413
Main Authors: Bozcuk, Hakan, Artaç, Mehmet, Mutlu, Hasan, Sever, Özlem, Yıldırım, Mustafa
Format: Article
Language:English
Subjects:
B7-H1 Antigen - antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung - drug therapy
Humans
Immune Checkpoint Inhibitors - therapeutic use
Lung Neoplasms - drug therapy
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Retreatment
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, and this paper is designed to answer these clinical questions. Methods For this Meta-analysis, we searched PubMed, Science of Web, “Clinicaltrials.gov” and online sources for trials comparing PD-1 and PDL-1 CPIs in advanced NSCLC. The data for Hazard Ratio (HR) and their Confidence Intervals (CI) for Overall Survival (OS) was extracted. Results A sum of 9739 patients from 16 trials were included in the efficacy evaluation. For the OS endpoint, both PD-1 inhibitors (HR = 0.76, 95%CI = 0.69–0.83, P 
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155220964903